
Chinese General Practice ›› 2021, Vol. 24 ›› Issue (30): 3794-3798.DOI: 10.12114/j.issn.1007-9572.2021.02.002
Special Issue: 肿瘤最新文章合辑; 乳腺癌最新文章合辑
• Monographic Research • Previous Articles Next Articles
Published:2021-10-20
Online:2021-10-20
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.002
| [1]KUSAMA S,SPRATT J S Jr,DONEGAN W L,et al. The cross rates of growth of human mammary carcinoma[J].Cancer,1972,30(2):594-599.DOI:10.1002/1097-0142(197208)30:2<594:aid-cncr2820300241>3.0.co;2-2. [2]FRIBERG S,MATTSON S.On the growth rates of human malignant tumors:implications for medical decision making[J].J Surg Oncol,1997,65(4):284-297.DOI:10.1002/(sici)1096-9098(199708)65:4<284:aid-jso11>3.0.co;2-2. [3]DUFFY S W,CHEN H H,TABAR L,et al. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase[J].Stat Med,1995,14(14):1531-1543.DOI:10.1002/sim.4780141404. [4]LEE S,HUANG H,ZELEN M.Early detection of disease and scheduling of screening examinations[J].Stat Methods Med Res,2004,13(6):443-456.DOI:10.1191/0962280204sm377ra. [5]TAGHIPOUR S,BANJEVIC D,MILLER A B,et al. Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study[J].Br J Cancer,2013,108(3):542-548.DOI:10.1038/bjc.2012.596. [6]LAI M S,YEN M F,KUO H S,et al. Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases:Taiwan multicentre cancer screening (TAMCAS)[J].Int J Cancer,1998,78(1):21-26.DOI:10.1002/(sici)1097-0215(19980925)78:1<21:aid-ijc5>3.0.co;2-z. [7]WU J C Y,HAKAMA M,ANTTILA A,et al. Estimation of natural history parameters of breast cancer based on non-randomized organized screening data:subsidiary analysis of effects of inter-screening interval,sensitivity,and attendance rate on reduction of advanced cancer[J].Breast Cancer Res Treat,2010,122(2):553-566.DOI:10.1007/s10549-009-0701-x. [8]TAN K H,SIMONELLA L,WEE H L,et al. Quantifying the natural history of breast cancer[J].Br J Cancer,2013,109(8):2035-2043.DOI:10.1038/bjc.2013.471. [9]WU Y Y,YEN M F,YU C P,et al. Risk assessment of multistate progression of breast tumor with state-dependent genetic and environmental covariates[J].Risk Anal,2014,34(2):367-379.DOI:10.1111/risa.12116. [10]FRYBACK D G,STOUT N K,ROSENBERG M A,et al. The Wisconsin breast cancer epidemiology simulation model[J].J Natl Cancer Inst Monogr,2006(36):37-47.DOI:10.1093/jncimonographs/lgj007. [11]ALAGOZ O,ERGUN M A,CEVIK M,et al. The University of Wisconsin Breast Cancer Epidemiology Simulation Model:an update[J].Med Decis Making,2018,38(1_suppl):99S-111.DOI:10.1177/0272989x17711927. [12]WONG I O,KUNTZ K M,COWLING B J,et al. Cost effectiveness of mammography screening for Chinese women[J].Cancer,2007,110(4):885-895.DOI:10.1002/cncr.22848. [13]KIM J K,KIM H D,JUN M J,et al. Correction to:tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma[J].Dig Dis Sci,2017,62(11):3259.DOI:10.1007/s10620-017-4785-6. [14]KIM J K,KIM H D,JUN M J,et al. Tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma[J].Dig Dis Sci,2017,62(10):2923-2931.DOI:10.1007/s10620-017-4708-6. [15]SABRA M M,SHERMAN E J,TUTTLE R M.Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic,follicular cell-derived thyroid carcinoma[J].Cancer,2017,123(15):2955-2964.DOI:10.1002/cncr.30690. [16]WEEDON-FEKJAER H,LINDQVIST B H,VATTEN L J,et al. Breast cancer tumor growth estimated through mammography screening data[J].Breast Cancer Res,2008,10(3):R41.DOI:10.1186/bcr2092. [17]TAGHIPOUR S,CAUDRELIER L N,MILLER A B,et al. Using simulation to model and validate invasive breast cancer progression in women in the study and control groups of the Canadian National Breast Screening StudiesⅠandⅡ[J].Med Decis Making,2017,37(2):212-223.DOI:10.1177/0272989X16660711. [18]BREKELMANS C T,WESTERS P,FABER J A,et al. Age specific sensitivity and sojourn time in a breast cancer screening programme (DOM) in The Netherlands:a comparison of different methods[J].J Epidemiol Community Health,1996,50(1):68-71.DOI:10.1136/jech.50.1.68. [19]TABAR L,FAGERBERG G,CHEN H H,et al. Efficacy of breast cancer screening by age.New results from the Swedish Two-County Trial[J].Cancer,1995,75(10):2507-2517.DOI:10.1002/1097-0142(19950515)75:10<2507:aid-cncr2820751017>3.0.co;2-h. [20]PACI E,DUFFY S W.Modelling the analysis of breast cancer screening programmes:sensitivity,lead time and predictive value in the Florence District Programme (1975—1986)[J].Int J Epidemiol,1991,20(4):852-858.DOI:10.1093/ije/20.4.852. [21]JIANG H,WALTER S D,BROWN P E,et al. Estimation of screening sensitivity and sojourn time from an organized screening program[J].Cancer Epidemiol,2016,44:178-185.DOI:10.1016/j.canep.2016.08.021. [22]TABBANE F,BAHI J,RAHAL K,et al. Inflammatory symptoms in breast cancer.Correlations with growth rate,clinicopathologic variables,and evolution[J].Cancer,1989,64(10):2081-2089.DOI:10.1002/1097-0142(19891115)64:10<2081:aid-cncr2820641019>3.0.co;2-7. [23]KUROISHI T,TOMINAGA S,MORIMOTO T,et al. Tumor growth rate and prognosis of breast cancer mainly detected by mass screening[J].Jpn J Cancer Res,1990,81(5):454-462.DOI:10.1111/j.1349-7006.1990.tb02591.x. [24]LUNDGREN B.Observations on growth rate of breast carcinomas and its possible implications for lead time[J].Cancer,1977,40(4):1722-1725.DOI:10.1002/1097-0142(197710)40:4<1722:aid-cncr2820400448>3.0.co;2-2. [25]VON FOURNIER D,WEBER E,HOEFFKEN W,et al. Growth rate of 147 mammary carcinomas[J].Cancer,1980,45(8):2198-2207.DOI:10.1002/1097-0142(19800415)45:8<2198:aid-cncr2820450832>3.0.co;2-7. [26]PEER P G,VAN DIJCK J A,HENDRIKS J H,et al. Age-dependent growth rate of primary breast cancer[J].Cancer,1993,71(11):3547-3551.DOI:10.1002/1097-0142(19930601)71:11<3547:aid-cncr2820711114>3.0.co;2-c. [27]OTTEN J D,VAN SCHOOR G,PEER P G,et al. Growth rate of invasive ductal carcinomas from a screened 50-74-year-old population[J].J Med Screen,2018,25(1):40-46.DOI:10.1177/0969141316687791. [28]马恒敏,王乐,石菊芳,等. 乳腺癌自然史模型研究系统评价:现状及构建中国人群特异性模型面临的挑战[J].中华流行病学杂志,2017,38(10):1419-1425.DOI:10.3760/cma.j.issn.0254-6450.2017.10.025. MA H L,WANG L,SHI J F,et al. A systematic review of international simulation models on the natural history of breast cancer:current understanding and challenges for Chinese-population-specific model development [J].Chin J Epidemiol,2017,38(10):1419-1425.DOI:10.3760/cma.j.issn.0254-6450.2017.10.025. [29]FRACHEBOUD J,GROENEWOUD J H,BOER R,et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening[J].Int J Cancer,2006,118(8):2020-2025.DOI:10.1002/ijc.21560. [30]TILANUS-LINTHORST M M,KRIEGE M,BOETES C,et al. Hereditary breast cancer growth rates and its impact on screening policy[J].Eur J Cancer,2005,41(11):1610-1617.DOI:10.1016/j.ejca.2005.02.034. [31]TILANUS-LINTHORST M M,OBDEIJN I M,HOP W C,et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch,United Kingdom,and Canadian magnetic resonance imaging screening trials[J].Clin Cancer Res,2007,13(24):7357-7362.DOI:10.1158/1078-0432.CCR-07-0689. [32]KRIEGE M,BREKELMANS C T,BOETES C,et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition[J].N Engl J Med,2004,351(5):427-437.DOI:10.1056/nejmoa031759. [33]BREKELMANS C T,SEYNAEVE C,BARTELS C C,et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk[J].J Clin Oncol,2001,19(4):924-930.DOI:10.1200/JCO.2001.19.4.924. [34]CAUMO F,VECCHIATO F,STRABBIOLI M,et al. Interval cancers in breast cancer screening:comparison of stage and biological characteristics with screen-detected cancers or incident cancers in the absence of screening[J].Tumori,2010,96(2):198-201.DOI:10.1177/030089161009600203. [35]BREKELMANS C T,VAN GORP J M,PEETERS P H,et al. Histopathology and growth rate of interval breast carcinoma.Characterization of different subgroups[J].Cancer,1996,78(6):1220-1228.DOI:10.1002/(sici)1097-0142(19960915)78:6<1220:aid-cncr8>3.0.co;2-d. [36]NIXON R M,PHAROAH P,TABAR L,et al. Mammographic screening in women with a family history of breast cancer:some results from the Swedish two-county trial[J].Rev Epidemiol Sante Publique,2000,48(4):325-331. [37]CHEN T H,KUO H S,YEN M F,et al. Estimation of sojourn time in chronic disease screening without data on interval cases[J].Biometrics,2000,56(1):167-172.DOI:10.1111/j.0006-341x.2000.00167.x. [38]GENTILI C,SANFILIPPO O,SILVESTRINI R.Cell proliferation and its relationship to clinical features and relapse in breast cancers[J].Cancer,1981,48(4):974-979.DOI:10.1002/1097-0142(19810815)48:4<974:aid-cncr2820480420>3.0.co;2-#. [39]CHARLSON M E,FEINSTEIN A R.Rapid growth rate:a method of identifying node-negative breast cancer patients with a high risk of recurrence[J].J Chronic Dis,1983,36(12):847-853.DOI:10.1016/0021-9681(83)90005-x. [40]REBBECK T R,LEVIN A M,EISEN A,et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers[J].J Natl Cancer Inst,1999,91(17):1475-1479.DOI:10.1093/jnci/91.17.1475. [41]WOHLFAHRT J,ANDERSEN P K,MOURIDSEN H T,et al. Reproductive history and stage of breast cancer[J].Am J Epidemiol,1999,150(12):1325-1330.DOI:10.1093/oxfordjournals.aje.a009964. [42]RYU E B,CHANG J M,SEO M,et al. Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound[J].Eur Radiol,2014,24(9):2227-2235.DOI:10.1007/s00330-014-3256-0. [43]LEE S H,KIM Y S,HAN W,et al. Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography[J].Medicine (Baltimore),2016,95(37):e4874.DOI:10.1097/MD.0000000000004874. [44]YOO T K,MIN J W,KIM M K,et al. In vivo tumor growth rate measured by US in preoperative period and long term disease outcome in breast cancer patients[J].PLoS One,2015,10(12):e0144144.DOI:10.1371/journal.pone.0144144. [45]TABAR L,FAGERBERG G,CHEN H H,et al. Tumour development,histology and grade of breast cancers:prognosis and progression[J].Int J Cancer,1996,66(4):413-419.DOI:10.1002/(SICI)1097-0215(19960516)66:4<413:AID-IJC1>3.0.CO;2-Z. [46]GUNSOY N B,GARCIA-CLOSAS M,MOSS S M.Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom[J].Breast Cancer Res,2012,14(6):R152.DOI:10.1186/bcr3365. [47]MILLET I,BOUIC-PAGES E,HOA D,et al. Growth of breast cancer recurrences assessed by consecutive MRI[J].BMC Cancer,2011,11:155.DOI:10.1186/1471-2407-11-155. [48]DEMICHELI R,TERENZIANI M,BONADONNA G.Estimate of tumor growth time for breast cancer local recurrences:rapid growth after wake-up? [J].Breast Cancer Res Treat,1998,51(2):133-137.DOI:10.1023/a:1005887422022. [49]F?RNVIK D,L?NG K,ANDERSSON I,et al. Estimates of breast cancer growth rate from mammograms and its relation to tumour characteristics[J].Radiat Prot Dosimetry,2016,169(1/2/3/4):151-157.DOI:10.1093/rpd/ncv417. [50]HEUSER L,SPRATT J S,POLK H C.Growth rates of primary breast cancers[J].Cancer,1979,43(5):1888-1894.DOI:10.1002/1097-0142(197905)43:5<1888:aid-cncr2820430545>3.0.co;2-m. [51]GALANTE E,GALLUS G,GUZZON A,et al. Growth rate of primary breast cancer and prognosis:observations on a 3- to 7-year follow-up in 180 breast cancers[J].Br J Cancer,1986,54(5):833-836.DOI:10.1038/bjc.1986.247. [52]TUBIANA M,KOSCIELNY S.Natural history of human breast cancer:recent data and clinical implications[J].Breast Cancer Res Treat,1991,18(3):125-140.DOI:10.1007/BF01990028. [53]ABRAHAMSSON L,CZENE K,HALL P,et al. Breast cancer tumour growth modelling for studying the association of body size with tumour growth rate and symptomatic detection using case-control data[J].Breast Cancer Res,2015,17:116.DOI:10.1186/s13058-015-0614-z. [54]BATINA N G,TRENTHAM-DIETZ A,GANGNON R E,et al. Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis[J].Breast Cancer Res Treat,2013,138(2):519-528.DOI:10.1007/s10549-013-2435-z. |
| [1] | FENG Yuxi, WANG Jinjin, CAI Yi, ZHU Runzhi, ZHU Qin. Research Progress on Protein Lactylation in Kidney Diseases [J]. Chinese General Practice, 2026, 29(21): 3056-3063. |
| [2] | LI Wenping, CHEN Jianhua, XU Jiapei, JIN Xue, PAN Zihan, CHI Chunhua. A Scoping Review on the Empowerment of Community Elderly Health Services by Digital-Intelligent Health Management Platforms [J]. Chinese General Practice, 2026, 29(21): 2938-2949. |
| [3] | CHENG Yu, HAN Shiyao, SUN Ping, XIANG Juan, YANG Hui, LI Dongze, ZHENG Li, LIAO Xiaoyang. Analysis of Socioeconomic and Demographic Challenges in Chronic Disease Management [J]. Chinese General Practice, 2026, 29(20): 2800-2807. |
| [4] | CHEN Yiping, ZHANG Jianmei, LI Yanhu, LI Rui, ZHANG Ruiping, YANG Ping. Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury [J]. Chinese General Practice, 2026, 29(18): 2585-2592. |
| [5] | ZHANG Mingyue, HOU Yan. Research Progress of Exhaled Nitric Oxide and Alveolar Nitric Oxide in Interstitial Lung Diseases [J]. Chinese General Practice, 2026, 29(18): 2571-2576. |
| [6] | MA Xiaoyu, MA Xiaomei, WU Guozhi, ZHENG Ya, GUO Qinghong. Research Progress of Neutrophil Extracellular Traps in Gastric Cancer [J]. Chinese General Practice, 2026, 29(17): 2425-2432. |
| [7] | LI Jiawei, GE Aoqi, GAO Xinyi, LI Juanjuan, YUAN Beibei. The Concept, Connotation, and Pathways of the Integration of Medical Care and Preventive Services in China: a Systematic Review [J]. Chinese General Practice, 2026, 29(16): 2156-2166. |
| [8] | WANG Yang, JIN Hua, YANG Sen, YANG Hui, YU Dehua. Reconfiguring the Functional Features of Primary Care in a Non-gatekeeping Context: a 15-Year Mixed-methods Systematic Review from China [J]. Chinese General Practice, 2026, 29(16): 2140-2155. |
| [9] | ZOU Jian, LI Wanping, GE Handa, JIN Zhe, RUFEINA· Tuerxun, LI Juan, WEI Anhua, FENG Da. Study on Potentially Inappropriate Medication Use among the Community Elderly Patients in Hubei Province [J]. Chinese General Practice, 2026, 29(13): 1759-1765. |
| [10] | ZHANG Qiang, ZHAO Wenxia, WANG Ziyi, YAN Le, LIANG Haowei, WANG Jinfan, FANG Jinhua, LU Cuncun. Interpretation of the Reporting Guideline for Systematic Reviews of Outcome Measurement Instruments (PRISMA-COSMIN for OMIs 2024) [J]. Chinese General Practice, 2026, 29(13): 1766-1775. |
| [11] | YE Xinying, YIN Ankang, LIU Dingling, LYU Xiang, WANG Yi. The Development of General Practice Department in General Hospitals under the DIP Payment Model [J]. Chinese General Practice, 2026, 29(11): 1378-1384. |
| [12] | SHI Yufeng, LU Chenxia, LYU Anqi, LI Xiaodong. Research Progress on the Relationship between Veillonella and Liver Diseases Based on the Theory of Intestinal-hepatic Axis [J]. Chinese General Practice, 2026, 29(11): 1488-1496. |
| [13] | SUN Yuchen, SHI Yaxin, SHI Wei. Advancements in the Treatment of Endometrial Hypofunction Diseases Using Menstrual Blood-derived Endometrium Stem Cells Combined with Traditional Chinese Medicine for Tonifying Kidney and Activating Blood in Regenerative Medicine [J]. Chinese General Practice, 2026, 29(11): 1481-1487. |
| [14] | WANG Gaoming, WANG Minghang, YANG Jiang, MENG Yuanyuan, ZHAO Di, DONG Xiaosheng. Systematic Evaluation and Reflection on the Quality of Bronchial Asthma Guidelines in China [J]. Chinese General Practice, 2026, 29(10): 1239-1245. |
| [15] | WANG Yuqi, YE Ruixue, GAO Yan, XUE Kaiwen, ZHOU Jing, LI Dongxia, HAO Yingzi, LI Xiaoxuan, WANG Yulong. Rehabilitation Grading Diagnosis System of the Domestic and Foreign Development Present Situation and Application Requirements [J]. Chinese General Practice, 2026, 29(10): 1250-1255. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||